PE20230323A1 - Compuestos de azalactama como inhibidores de hpk1 - Google Patents

Compuestos de azalactama como inhibidores de hpk1

Info

Publication number
PE20230323A1
PE20230323A1 PE2022002503A PE2022002503A PE20230323A1 PE 20230323 A1 PE20230323 A1 PE 20230323A1 PE 2022002503 A PE2022002503 A PE 2022002503A PE 2022002503 A PE2022002503 A PE 2022002503A PE 20230323 A1 PE20230323 A1 PE 20230323A1
Authority
PE
Peru
Prior art keywords
compounds
azalactam
salts
6alkyl
hpk1 inhibitors
Prior art date
Application number
PE2022002503A
Other languages
English (en)
Inventor
Joyann Barber
Sujin Cho-Schultz
Bel Matthew L Del
Rebecca Anne Gallego
Mingying He
Mehran Jalaie
Robert Steven Kania
Michele Ann Mctigue
Sajiv Krishnan Nair
Anne-Marie Dechert Schmitt
Jamison Bryce Tuttle
Dahui Zhou
Ru Zhou
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20230323A1 publication Critical patent/PE20230323A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Se refiere a un compuesto de Formula I en donde R1 es alquiloC1-6, haloalquiloC1-6, etc; R2 es NR7R8, donde R7 y R8 son cada uno H, alquilo, etc; R3a y R3b son H, alquilo C1-3, etc y R4 es triazol opcionalmente sustituido, etc., y sales farmaceuticamente aceptables de los mismos, composiciones farmaceuticas que comprenden dichos compuestos y sales, y a metodos de uso de dichos compuestos, sales y composiciones para el tratamiento del crecimiento celular anormal, incluido el cancer.
PE2022002503A 2020-05-01 2021-04-28 Compuestos de azalactama como inhibidores de hpk1 PE20230323A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063018689P 2020-05-01 2020-05-01
PCT/IB2021/053522 WO2021220185A1 (en) 2020-05-01 2021-04-28 Azalactam compounds as hpk1 inhibitors

Publications (1)

Publication Number Publication Date
PE20230323A1 true PE20230323A1 (es) 2023-02-22

Family

ID=75769663

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022002503A PE20230323A1 (es) 2020-05-01 2021-04-28 Compuestos de azalactama como inhibidores de hpk1

Country Status (18)

Country Link
US (1) US11684616B2 (es)
EP (1) EP4143186A1 (es)
JP (1) JP7303948B2 (es)
KR (1) KR20230003128A (es)
CN (1) CN115698004A (es)
AR (1) AR121985A1 (es)
AU (1) AU2021265578B2 (es)
CA (1) CA3181415A1 (es)
CL (1) CL2022003007A1 (es)
CO (1) CO2022015448A2 (es)
CR (1) CR20220548A (es)
EC (1) ECSP22084264A (es)
IL (1) IL297838A (es)
MX (1) MX2022013401A (es)
PE (1) PE20230323A1 (es)
TW (1) TWI806043B (es)
UY (1) UY39193A (es)
WO (1) WO2021220185A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
TW202328152A (zh) 2021-10-05 2023-07-16 美商輝瑞大藥廠 氮雜內醯胺化合物之晶型
WO2023057882A1 (en) * 2021-10-05 2023-04-13 Pfizer Inc. Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
CA3041033A1 (en) 2016-09-12 2018-03-15 Numerate, Inc. Monocyclic compounds useful as gpr120 modulators
US10787435B2 (en) 2017-01-22 2020-09-29 Fuijan Cosunter Pharmaceutical Co. Ltd. ASK1 inhibitor and preparation method and use thereof
WO2018151830A1 (en) 2017-02-17 2018-08-23 Fronthera U.S. Pharmaceuticals Llc Pyridinyl based apoptosis signal-regulation kinase inhibitors
CN111094250B (zh) 2017-03-03 2022-11-04 江苏豪森药业集团有限公司 凋亡信号调节激酶抑制剂及其制备方法和应用
CN110402248B (zh) * 2017-03-15 2023-01-06 豪夫迈·罗氏有限公司 作为hpk1抑制剂的氮杂吲哚类
JOP20190221A1 (ar) 2017-04-05 2019-09-23 Seal Rock Therapeutics Inc مركبات مثبطات كيناز منظم لإشارات الاستماتة 1 (ask1) واستخداماتها
TW201908306A (zh) * 2017-07-18 2019-03-01 大陸商南京聖和藥業股份有限公司 作為ask抑制劑的雜環化合物及其應用
WO2019148005A1 (en) 2018-01-26 2019-08-01 Nurix Therapeutics, Inc. Inhibitors of cbl-b and methods of use thereof
US11142525B2 (en) * 2018-11-15 2021-10-12 Pfizer Inc. Azalactam compounds as HPK1 inhibitors
KR20220105631A (ko) 2019-09-13 2022-07-27 님버스 새턴 인코포레이티드 Hpk1 길항제 및 이의 용도
WO2021224818A1 (en) 2020-05-08 2021-11-11 Pfizer Inc. Isoindolone compounds as hpk1 inhibitors

Also Published As

Publication number Publication date
KR20230003128A (ko) 2023-01-05
TW202202496A (zh) 2022-01-16
CN115698004A (zh) 2023-02-03
CR20220548A (es) 2022-12-12
AR121985A1 (es) 2022-07-27
AU2021265578B2 (en) 2024-03-28
AU2021265578A1 (en) 2022-11-10
UY39193A (es) 2021-11-30
JP7303948B2 (ja) 2023-07-05
JP2023515900A (ja) 2023-04-14
IL297838A (en) 2023-01-01
US20220401424A1 (en) 2022-12-22
CO2022015448A2 (es) 2022-11-18
EP4143186A1 (en) 2023-03-08
CA3181415A1 (en) 2021-11-04
MX2022013401A (es) 2022-11-14
WO2021220185A1 (en) 2021-11-04
ECSP22084264A (es) 2022-11-30
TWI806043B (zh) 2023-06-21
US11684616B2 (en) 2023-06-27
CL2022003007A1 (es) 2023-06-16

Similar Documents

Publication Publication Date Title
PE20230323A1 (es) Compuestos de azalactama como inhibidores de hpk1
UY38553A (es) Inhibidores de cdk2
CL2019000368A1 (es) Inhibidores de cdk2/4/6.
CL2021001190A1 (es) Compuestos de azalactam como inhibidores de hpk1
ECSP21091615A (es) Derivados de benzisoxazol sulfonamida
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
UY37900A (es) Nuevos derivados de rapamicina
ECSP12012293A (es) Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos
CO6300846A2 (es) Derivados heterociclicos que contienen azufre que tienen actividad inhibitoria de la beta secretasa
ECSP22038509A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
CO2024001285A2 (es) Compuestos tricíclicos como inhibidores de kras
CO2023000703A2 (es) Métodos de tratamiento del cáncer mediante derivados heteroaril-bifenil-amida
CO2023017970A2 (es) Inhibidores de mutación de her2
UY39181A (es) COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO
CU20210044A7 (es) Pirazoles como moduladores de hemoglobina
MX2020013076A (es) Compuestos de acido ascorbico y quinona en combinacion con un agente antiparasitario para el tratamiento de una enfermedad parasitaria.
AR122805A1 (es) Inhibidores de mutación her2
UY39303A (es) Inhibidores de mutación her2
ECSP23075535A (es) Compuestos cíclicos y métodos de uso
AR126389A1 (es) Compuestos tricíclicos como inhibidores de kras
CU20140033A7 (es) Derivados de pirrolopirimidina y purina